Published in Physician Law Weekly, September 27th, 2006
According to recent research from Italy, "We wanted to assess the effectiveness and safety of glargine in the treatment of patients with type 2 diabetes mellitus in secondary failure and/or with severe comorbidities ('T2DM group'), and patients with secondary diabetes after corticosteroid and/or anticancer treatment ('secondary DM group'). We reviewed the records of patients on glargine from August 1, 2004 to July 30, 2005. The after-minus-before change in HbA1c was the main outcome measure."
A.V. Ciardullo and colleagues working with the Ramazzini...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Physician Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.